GTBP
GT Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.69
−4.84%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$7.17
From 52W high−70.94%
Volume28303.00
Market cap$12.07M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$7.17
From 52W high
−70.94%
Volume
28303.00
Market cap
$12.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
51.2
MomentumView details →
1D Return
−4.84%
YTD Return
−64.39%
SummaryUpdated Jun 1, 2026
GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage biopharmaceutical company founded in 1965 and headquartered in Brisbane, California. Originally incorporated as OXIS International, Inc., the company underwent a strategic transformation and rebranded to GT Biopharma in July 2017 to focus on developing innovative cancer immunotherapies. The company specializes in immuno-oncology treatments based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein technology platform, with multiple drug candidates currently in clinical and preclinical development stages.
Similar companies
Latest newsMore news →
GT Biopharma, Inc. entered a Joinder Agreement dated September 18, 2026, making Nicholas Nikolov a party to the Registration Rights Agreement dated September 14, 2026 with the same rights and obligations as an original signatory.28d agoGT Biopharma, Inc. amended its September 14, 2026 Securities Purchase Agreement to increase the aggregate stated value of Series M 10% Convertible Preferred Stock issuable from $8,277,778 to $8,611,111.11 for an aggregate purchase price of $7,750,000, adding Nicholas Nikolov as a new purchaser.28d agoGT Biopharma received FDA clearance of a new IND for GTB-5550 in multiple myeloma under an investigator-sponsored trial protocol.34d ago